Ftse Mib
38.456,17
0,09%
DAX
22.425,93
0,73%
S&P 500
6.018,64
0,09%
NASDAQ
19.478,50
-0,23%
Bitcoin
94.290,59
-2,06%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Adicet Bio Inc (ACET) Adicet Bio Inc (ACET) Notizie

Adicet Bio Inc

ACET
0,9984
0,025 (2,57%)
Ultimo aggiornamento: 20:02:59
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
05/2/202513:10BWAdicet Bio Receives FDA Fast Track Designation for ADI-001..
05/2/202513:01EDGAR2Form 8-K - Current report
04/2/202522:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/2/202522:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/2/202500:06BWAdicet Bio Reports Inducement Grants under Nasdaq Listing..
29/1/202513:00BWAdicet Bio to Participate in a Fireside Chat at the..
28/1/202522:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/1/202522:06EDGAR2Form 3 - Initial statement of beneficial ownership of..
08/1/202522:10BWAdicet Bio Provides Corporate Update and Highlights Expected..
31/12/202422:48BWAdicet Bio Reports Inducement Grant under Nasdaq Listing..
19/12/202422:00EDGAR2Form 8-K - Current report
19/12/202413:00BWAdicet Bio Announces First Patient Dosed in the Phase 1..
18/12/202413:00BWAdicet Bio Appoints Julie Maltzman, M.D. as Chief Medical..
29/11/202422:44BWAdicet Bio Reports Inducement Grant under Nasdaq Listing..
27/11/202423:12EDGAR2Form 8-K - Current report
18/11/202422:01EDGAR2Form 8-K - Current report
18/11/202422:00BWAdicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial..
18/11/202413:00BWAdicet Bio Announces First Lupus Nephritis Patient Dosed in..
16/11/202415:00BWAdicet Bio Presents Clinical Biomarker Data for..
15/11/202422:03EDGAR2Form 8-K - Current report
14/11/202422:05EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
13/11/202421:49EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
06/11/202422:03EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/11/202422:01EDGAR2Form 8-K - Current report
06/11/202422:00BWAdicet Reports Third Quarter 2024 Financial Results and..
05/11/202413:00BWAdicet Bio to Present at the American College of..
01/11/202412:00BWAdicet Bio to Participate in Upcoming Investor Conferences
31/10/202422:31BWAdicet Bio Reports Inducement Grants under Nasdaq Listing..
16/10/202413:01EDGAR2Form 8-K - Current report
16/10/202413:00BWAdicet Bio Announces FDA Clearance of IND Amendment to..
30/9/202423:08BWAdicet Bio Reports Inducement Grants under Nasdaq Listing..
30/9/202422:30BWAdicet Bio to Present at the American Society of Gene & Cell..
30/9/202413:01EDGAR2Form 8-K - Current report
30/9/202413:00BWAdicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial..
19/9/202413:01EDGAR2Form 8-K - Current report
19/9/202413:00BWADI-001 Clinical Biomarker Data Demonstrate Robust Tissue..
10/9/202413:01EDGAR2Form 8-K - Current report
30/8/202423:44BWAdicet Bio Reports Inducement Grants under Nasdaq Listing..
27/8/202422:00BWAdicet Bio to Present at the H.C. Wainwright 26th Annual..
23/8/202422:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/8/202422:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/8/202422:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/8/202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/8/202422:03EDGAR2Form 3 - Initial statement of beneficial ownership of..
19/8/202422:01EDGAR2Form 8-K - Current report
19/8/202413:00BWAdicet Bio Appoints Lloyd Klickstein, M.D., Ph.D. to the..
13/8/202413:04EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/8/202413:01EDGAR2Form 8-K - Current report
13/8/202413:00BWAdicet Reports Second Quarter 2024 Financial Results and..
01/8/202422:00BWAdicet Bio to Participate in Upcoming Investor Conferences
Apertura: 0,9701 Min: 0,9254 Max: 1,01
Chiusura: 0,9734

La tua Cronologia

NASDAQ
ACET
Adicet Bio
ASX
FMGIOD
BIT
WAGA25
Agatos
NASDAQ
ACT
Enact
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci